dc.contributor.author | López López, Carlos | |
dc.contributor.author | Calvo, Mariona | |
dc.contributor.author | Cámara, Juan Carlos | |
dc.contributor.author | García-Paredes, Beatriz | |
dc.contributor.author | Gómez-Martín, Carlos | |
dc.contributor.author | López, Ana María | |
dc.contributor.author | Pazo-Cid, Roberto | |
dc.contributor.author | Sastre, Javier | |
dc.contributor.author | Yaya, Ricardo | |
dc.contributor.author | Feliu, Jaime | |
dc.contributor.other | Universidad de Cantabria | es_ES |
dc.date.accessioned | 2024-10-23T14:09:32Z | |
dc.date.available | 2024-10-23T14:09:32Z | |
dc.date.issued | 2024 | |
dc.identifier.issn | 1699-048X | |
dc.identifier.issn | 1699-3055 | |
dc.identifier.uri | https://hdl.handle.net/10902/34332 | |
dc.description.abstract | Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child-Pugh class A. | es_ES |
dc.description.sponsorship | Acknowledgements: The authors thank Dr Angela Lamarca (Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain) and Dr Roberto Díaz Beveridge (Hospital Universitario y Politécnico la Fe, Valencia, Spain) for the review of the guidelines and validation of the level of evidence and grade of recommendations. | es_ES |
dc.format.extent | 12 p. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer-Verlag Italia | es_ES |
dc.rights | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.source | Clinical and Translational Oncology, 2024, 26, 2800-2811 | es_ES |
dc.subject.other | Hepatocellular carcinoma | es_ES |
dc.subject.other | Guidelines | es_ES |
dc.subject.other | Diagnostic | es_ES |
dc.subject.other | Staging | es_ES |
dc.subject.other | Treatment | es_ES |
dc.title | SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023) | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.identifier.DOI | 10.1007/s12094-024-03568-4 | |
dc.type.version | publishedVersion | es_ES |